# Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure

> **NCT00676234** · PHASE2 · COMPLETED · sponsor: **University Hospital, Geneva** · enrollment: 80 (estimated)

## Conditions studied

- Acute Renal Failure

## Interventions

- **DRUG:** epoetinum

## Key facts

- **NCT ID:** NCT00676234
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2009-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676234, "Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00676234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*